The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

10/03/2016 - 3 minutes

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target…

aprea_apr-246_p53_protein_ovarian_cancer_versant_ventures_5am_ventures_healthcap_karolinska_developmentAprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program.

This Biotech has a promising candidate for the treatment of Ovarian cancer (and potentially other types too). The therapy (APR-246) is based on the reactivation of the p53 protein. If the drug makes it to the market, it would be the first to successfully target the p53 pathway.

The p53 tumour suppressor gene is the most frequently mutated gene in human cancer – 50% of all human tumours carry it. Protein p53 is a key in tumour suppression, and mutated p53 is often associated with resistance to anticancer drugs and poor overall survival – so it is a major unmet medical need in the cancer field.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member